Investigating how blood vessel invasion affects cancer spread in colorectal cancer
Official title: EMVI as a Determinant of Metastasis in Colorectal Cancer
Run by Imperial College London · NCT06646341 · Data updated 2026-11-12
This study is trying to see if cancer spreading through blood vessels makes colorectal cancer worse than if it spreads through lymph nodes by looking at tissue samples from patients who had surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years to 100 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Imperial College London Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Basingstoke, Hampshire) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2027 |
| Registry record updated | November 1, 2024 |
| Trial ID | NCT06646341 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 16 years or older who have undergone surgical removal of their colorectal cancer and any distant metastases.
✕Probably not a fit
Patients who have had a complete pathological response in their primary tumor or those with inadequate tissue samples will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between Extramural Venous Invasion (EMVI) and the development of distant metastases in colorectal cancer. By analyzing archival tissue samples from patients who have undergone surgery for colorectal cancer, the study will assess whether cancer spreads more significantly through blood vessels rather than lymph nodes. The research will utilize genetic material from tumors to reconstruct phylogenetic trees, comparing the origins of primary tumors, EMVI, tumor deposits, lymph nodes, and distant metastases. The findings could lead to a major shift in how metastatic disease is understood and treated.
Why it matters
Potential benefit: If successful, this study could improve the identification of patients who would benefit from targeted adjuvant treatments, potentially enhancing survival rates.
How similar studies have gone: While the approach of examining blood vessel invasion in cancer spread is gaining attention, this specific study's focus on EMVI in colorectal cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Are aged 16 years or over with colorectal cancer 2. Colon / rectum has been surgically removed 3. Distant metastases has been surgically removed 4. Pre operative staging in the form of CT/MRI has been undertaken and images available for review Exclusion Criteria: 1. Pathological complete response in the primary tumour 2. Local resection of the primary tumour 3. Inadequate quantity of tissue sample to perform analyses
Where it's running
-
Hampshire Hospitals Nhs Foundation Trust
Basingstoke, Hampshire, United Kingdom Recruiting
Study contacts
- Principal investigator: Gina Brown, MD — Imperial College London
- Study coordinator: Caroline Martin
- Email: c.martin1@imperial.ac.uk
- Phone: +44 (0) 7749 655 817
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prehabilitation before high-risk cancer surgery
This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.
-
Personal cancer risk testing using genetic, blood, and tumor monitoring
This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.
-
Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease
This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.
-
Colorectal Cancer Screening Outreach for Better Adherence
This trial tests a bundled messaging approach to help adults at risk complete colorectal cancer screening.
-
Blood-based delta-HLD methylation test for detecting colorectal cancer
This will try a blood-based delta-HLD methylation test to see if it can detect colorectal cancer in people scheduled for colonoscopy or colorectal surgery.
-
MBRC-201 dose-finding and safety in advanced metastatic solid tumors
We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.